Trial
NCT01412515
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators
—
Condition
Kaposi Sarcoma
Intervention
everolimus
Why stopped
results from interim analysis conducted to study interruption
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-04